Search | Page 31 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Related Diseases

    ... the bone marrow and interfere with the body’s normal blood cell production. ... versus host disease (GVHD) is a common complication of a stem cell/ bone marrow transplant . It happens when the donor's immune ...

    Page last updated 07/07/2016 - 3:16pm.

  2. Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

    ... of improvement (relapsed), previously treated with donor stem cell transplant . Biological therapies, such as cellular adoptive immunotherapy, ...

    Clinical Trial last updated 04/29/2016 - 10:34am.

  3. RIC Transplant Using Haplo Donors

    ... -mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the incidence of ...

    Clinical Trial last updated 04/29/2016 - 10:52am.

  4. Phase I, Dose Escalation Study of Decitabine

    ... that Decitabine delivered after allo-hematopoietic stem cell transplant (HSCT) in patients with leukemia will enhance disease ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  5. A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

    ... of differentiation (CD)-34+ allogeneic peripheral blood stem cell transplantation (PBSCT) on day 0. GVHD PROPHYLAXIS: Beginning on day ...

    Clinical Trial last updated 04/27/2016 - 1:56pm.

  6. Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant

    ... side effects and best dose of selinexor when given after stem cell transplant in treating patients with acute myeloid leukemia that is at ...

    Clinical Trial last updated 04/29/2016 - 10:38am.

  7. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

    ... sibling donor or are too old for hematopoietic stem cell transplant . Approximately two thirds of patients successfully respond ...

    Research Review last updated 05/02/2016 - 9:13am.

  8. Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

    ... use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to ...

    Clinical Trial last updated 05/03/2016 - 11:45am.

  9. Randomized Allogeneic Azacitidine Study

    ... with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant . The safety of this drug will also be studied. ...

    Clinical Trial last updated 05/03/2016 - 11:08am.

  10. A Phase II Study of 5-Azacitidine and Sargramostim as Maintenance Treatment After Definitive Therapy for Poor-risk AML or MDS

    ... are in remission after definitive treatment with either stem cell transplant or cytarabine-based consolidation chemotherapy . ...

    Clinical Trial last updated 05/03/2016 - 10:38am.